Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
Weight reduction is the most important treatment target when polycystic ovary syndrome (PCOS) is linked to obesity. Liraglutide (LIRA) in dose of 3 mg was recently approved as an anti-obesity drug. Metformin could enhance weight lowering potential of liraglutide. We investigates short term interventions with low dose liraglutide in combination with metformin and high dose liraglutide alone influence on significant weight reduction in obese women with PCOS.
Epistemonikos ID: 13d04ba1e9f8dd7d261469e0301264740cd0373f
First added on: May 17, 2024